Industry Research Reports
Global Varicella Vaccine Market Research Report 2026
Industry: Pharma & Healthcare
Published Date: 2026-01-04
Pages: 114 Pages
Report ld: 5528428
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Varicella Vaccine Market Size(US$)
CAGR 2026-2032
7.8%
Market Size,2032
USD 8,708
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 5,549 million
Market Forecast in 2032(Value)
US$ 8,708 million
CAGR
7.8%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Varicella Vaccine market was valued at US$ 5185 million in 2025 and is anticipated to reach US$ 8708 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Varicella Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Global Varicella Vaccine key players include Merck, Shanghai Institute, Changsheng, Keygen, GSK, etc.
Asia is the largest market, with a share over 35%, followed by US and Europe, both have a share over 55%.
In terms of product, Freeze-Dried Powder is the largest segment, with a share over 50%. And in terms of application, the largest application is Kids Injection, followed by Adults Injection, etc.
This report delivers a comprehensive overview of the global Varicella Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Varicella Vaccine. The Varicella Vaccine market size, estimates, and forecasts are provided in terms of sales volume (M Doses) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Varicella Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Varicella Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
MARKET SEGMENTATION
By Company
- Merck
- GSK
- Shanghai Institute
- BCHT
- Changsheng
- Keygen
- Green Cross
- Biken
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Injection
- Freeze-Dried Powder
Segment by Application
- Kids Injection
- Adults Injection
CHAPTER OUTLINE
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Varicella Vaccine manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Varicella Vaccine sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Varicella Vaccine Market Overview
1.1 Product Definition
1.2 Varicella Vaccine by Type
1.2.1 Global Varicella Vaccine Market Value by Type: 2025 vs 2032
1.2.2 Injection
1.2.3 Freeze-Dried Powder
1.3 Varicella Vaccine by Application
1.3.1 Global Varicella Vaccine Market Value by Application: 2025 vs 2032
1.3.2 Kids Injection
1.3.3 Adults Injection
1.4 Global Varicella Vaccine Market Size Estimates and Forecasts
1.4.1 Global Varicella Vaccine Revenue 2021–2032
1.4.2 Global Varicella Vaccine Sales 2021–2032
1.4.3 Global Varicella Vaccine Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Varicella Vaccine Market Competition by Manufacturers
2.1 Global Varicella Vaccine Sales Market Share by Manufacturers (2021–2026)
2.2 Global Varicella Vaccine Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Varicella Vaccine Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Varicella Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Varicella Vaccine, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Varicella Vaccine, Product Types and Applications
2.7 Global Key Manufacturers of Varicella Vaccine, Date of Entry into the Industry
2.8 Global Varicella Vaccine Market Competitive Situation and Trends
2.8.1 Global Varicella Vaccine Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Varicella Vaccine Players Market Share by Revenue
2.8.3 Global Varicella Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Varicella Vaccine Market Scenario by Region
3.1 Global Varicella Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Varicella Vaccine Sales by Region: 2021–2032
3.2.1 Global Varicella Vaccine Sales by Region: 2021–2026
3.2.2 Global Varicella Vaccine Sales by Region: 2027–2032
3.3 Global Varicella Vaccine Revenue by Region: 2021–2032
3.3.1 Global Varicella Vaccine Revenue by Region: 2021–2026
3.3.2 Global Varicella Vaccine Revenue by Region: 2027–2032
3.4 North America Varicella Vaccine Market Facts & Figures by Country
3.4.1 North America Varicella Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Varicella Vaccine Sales by Country (2021–2032)
3.4.3 North America Varicella Vaccine Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Varicella Vaccine Market Facts & Figures by Country
3.5.1 Europe Varicella Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Varicella Vaccine Sales by Country (2021–2032)
3.5.3 Europe Varicella Vaccine Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Varicella Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Varicella Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Varicella Vaccine Sales by Region (2021–2032)
3.6.3 Asia Pacific Varicella Vaccine Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Varicella Vaccine Market Facts & Figures by Country
3.7.1 Latin America Varicella Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Varicella Vaccine Sales by Country (2021–2032)
3.7.3 Latin America Varicella Vaccine Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Varicella Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Varicella Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Varicella Vaccine Sales by Country (2021–2032)
3.8.3 Middle East and Africa Varicella Vaccine Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Varicella Vaccine Sales by Type (2021–2032)
4.1.1 Global Varicella Vaccine Sales by Type (2021–2026)
4.1.2 Global Varicella Vaccine Sales by Type (2027–2032)
4.1.3 Global Varicella Vaccine Sales Market Share by Type (2021–2032)
4.2 Global Varicella Vaccine Revenue by Type (2021–2032)
4.2.1 Global Varicella Vaccine Revenue by Type (2021–2026)
4.2.2 Global Varicella Vaccine Revenue by Type (2027–2032)
4.2.3 Global Varicella Vaccine Revenue Market Share by Type (2021–2032)
4.3 Global Varicella Vaccine Price by Type (2021–2032)
5 Segment by Application
5.1 Global Varicella Vaccine Sales by Application (2021–2032)
5.1.1 Global Varicella Vaccine Sales by Application (2021–2026)
5.1.2 Global Varicella Vaccine Sales by Application (2027–2032)
5.1.3 Global Varicella Vaccine Sales Market Share by Application (2021–2032)
5.2 Global Varicella Vaccine Revenue by Application (2021–2032)
5.2.1 Global Varicella Vaccine Revenue by Application (2021–2026)
5.2.2 Global Varicella Vaccine Revenue by Application (2027–2032)
5.2.3 Global Varicella Vaccine Revenue Market Share by Application (2021–2032)
5.3 Global Varicella Vaccine Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Company Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Varicella Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Merck Varicella Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Varicella Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 GSK Varicella Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Shanghai Institute
6.3.1 Shanghai Institute Company Information
6.3.2 Shanghai Institute Description and Business Overview
6.3.3 Shanghai Institute Varicella Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Shanghai Institute Varicella Vaccine Product Portfolio
6.3.5 Shanghai Institute Recent Developments/Updates
6.4 BCHT
6.4.1 BCHT Company Information
6.4.2 BCHT Description and Business Overview
6.4.3 BCHT Varicella Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 BCHT Varicella Vaccine Product Portfolio
6.4.5 BCHT Recent Developments/Updates
6.5 Changsheng
6.5.1 Changsheng Company Information
6.5.2 Changsheng Description and Business Overview
6.5.3 Changsheng Varicella Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Changsheng Varicella Vaccine Product Portfolio
6.5.5 Changsheng Recent Developments/Updates
6.6 Keygen
6.6.1 Keygen Company Information
6.6.2 Keygen Description and Business Overview
6.6.3 Keygen Varicella Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Keygen Varicella Vaccine Product Portfolio
6.6.5 Keygen Recent Developments/Updates
6.7 Green Cross
6.7.1 Green Cross Company Information
6.7.2 Green Cross Description and Business Overview
6.7.3 Green Cross Varicella Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Green Cross Varicella Vaccine Product Portfolio
6.7.5 Green Cross Recent Developments/Updates
6.8 Biken
6.8.1 Biken Company Information
6.8.2 Biken Description and Business Overview
6.8.3 Biken Varicella Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Biken Varicella Vaccine Product Portfolio
6.8.5 Biken Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Varicella Vaccine Industry Chain Analysis
7.2 Varicella Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Varicella Vaccine Production Mode & Process Analysis
7.4 Varicella Vaccine Sales and Marketing
7.4.1 Varicella Vaccine Sales Channels
7.4.2 Varicella Vaccine Distributors
7.5 Varicella Vaccine Customer Analysis
8 Varicella Vaccine Market Dynamics
8.1 Varicella Vaccine Industry Trends
8.2 Varicella Vaccine Market Drivers
8.3 Varicella Vaccine Market Challenges
8.4 Varicella Vaccine Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Varicella Vaccine Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Varicella Vaccine Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Varicella Vaccine Market Competitive Situation by Manufacturers in 2025
Table 4. Global Varicella Vaccine Sales (M Doses) of Key Manufacturers (2021–2026)
Table 5. Global Varicella Vaccine Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Varicella Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Varicella Vaccine Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Varicella Vaccine Average Price (USD/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Varicella Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Varicella Vaccine, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Varicella Vaccine, Product Types and Applications
Table 12. Global Key Manufacturers of Varicella Vaccine, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Varicella Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on Varicella Vaccine Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Varicella Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Varicella Vaccine Sales by Region (M Doses), 2021–2026
Table 18. Global Varicella Vaccine Sales Market Share by Region (2021–2026)
Table 19. Global Varicella Vaccine Sales by Region (M Doses), 2027–2032
Table 20. Global Varicella Vaccine Sales Market Share by Region (2027–2032)
Table 21. Global Varicella Vaccine Revenue by Region (US$ Million), 2021–2026
Table 22. Global Varicella Vaccine Revenue Market Share by Region (2021–2026)
Table 23. Global Varicella Vaccine Revenue by Region (US$ Million), 2027–2032
Table 24. Global Varicella Vaccine Revenue Market Share by Region (2027–2032)
Table 25. North America Varicella Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Varicella Vaccine Sales by Country (M Doses), 2021–2026
Table 27. North America Varicella Vaccine Sales by Country (M Doses), 2027–2032
Table 28. North America Varicella Vaccine Revenue by Country (US$ Million), 2021–2026
Table 29. North America Varicella Vaccine Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Varicella Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Varicella Vaccine Sales by Country (M Doses), 2021–2026
Table 32. Europe Varicella Vaccine Sales by Country (M Doses), 2027–2032
Table 33. Europe Varicella Vaccine Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Varicella Vaccine Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Varicella Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Varicella Vaccine Sales by Region (M Doses), 2021–2026
Table 37. Asia Pacific Varicella Vaccine Sales by Region (M Doses), 2027–2032
Table 38. Asia Pacific Varicella Vaccine Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Varicella Vaccine Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Varicella Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Varicella Vaccine Sales by Country (M Doses), 2021–2026
Table 42. Latin America Varicella Vaccine Sales by Country (M Doses), 2027–2032
Table 43. Latin America Varicella Vaccine Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Varicella Vaccine Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Varicella Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Varicella Vaccine Sales by Country (M Doses), 2021–2026
Table 47. Middle East and Africa Varicella Vaccine Sales by Country (M Doses), 2027–2032
Table 48. Middle East and Africa Varicella Vaccine Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Varicella Vaccine Revenue by Country (US$ Million), 2027–2032
Table 50. Global Varicella Vaccine Sales (M Doses) by Type (2021–2026)
Table 51. Global Varicella Vaccine Sales (M Doses) by Type (2027–2032)
Table 52. Global Varicella Vaccine Sales Market Share by Type (2021–2026)
Table 53. Global Varicella Vaccine Sales Market Share by Type (2027–2032)
Table 54. Global Varicella Vaccine Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Varicella Vaccine Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Varicella Vaccine Revenue Market Share by Type (2021–2026)
Table 57. Global Varicella Vaccine Revenue Market Share by Type (2027–2032)
Table 58. Global Varicella Vaccine Price (USD/Dose) by Type (2021–2026)
Table 59. Global Varicella Vaccine Price (USD/Dose) by Type (2027–2032)
Table 60. Global Varicella Vaccine Sales (M Doses) by Application (2021–2026)
Table 61. Global Varicella Vaccine Sales (M Doses) by Application (2027–2032)
Table 62. Global Varicella Vaccine Sales Market Share by Application (2021–2026)
Table 63. Global Varicella Vaccine Sales Market Share by Application (2027–2032)
Table 64. Global Varicella Vaccine Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Varicella Vaccine Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Varicella Vaccine Revenue Market Share by Application (2021–2026)
Table 67. Global Varicella Vaccine Revenue Market Share by Application (2027–2032)
Table 68. Global Varicella Vaccine Price (USD/Dose) by Application (2021–2026)
Table 69. Global Varicella Vaccine Price (USD/Dose) by Application (2027–2032)
Table 70. Merck Company Information
Table 71. Merck Description and Business Overview
Table 72. Merck Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 73. Merck Varicella Vaccine Product
Table 74. Merck Recent Developments/Updates
Table 75. GSK Company Information
Table 76. GSK Description and Business Overview
Table 77. GSK Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 78. GSK Varicella Vaccine Product
Table 79. GSK Recent Developments/Updates
Table 80. Shanghai Institute Company Information
Table 81. Shanghai Institute Description and Business Overview
Table 82. Shanghai Institute Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 83. Shanghai Institute Varicella Vaccine Product
Table 84. Shanghai Institute Recent Developments/Updates
Table 85. BCHT Company Information
Table 86. BCHT Description and Business Overview
Table 87. BCHT Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 88. BCHT Varicella Vaccine Product
Table 89. BCHT Recent Developments/Updates
Table 90. Changsheng Company Information
Table 91. Changsheng Description and Business Overview
Table 92. Changsheng Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 93. Changsheng Varicella Vaccine Product
Table 94. Changsheng Recent Developments/Updates
Table 95. Keygen Company Information
Table 96. Keygen Description and Business Overview
Table 97. Keygen Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 98. Keygen Varicella Vaccine Product
Table 99. Keygen Recent Developments/Updates
Table 100. Green Cross Company Information
Table 101. Green Cross Description and Business Overview
Table 102. Green Cross Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 103. Green Cross Varicella Vaccine Product
Table 104. Green Cross Recent Developments/Updates
Table 105. Biken Company Information
Table 106. Biken Description and Business Overview
Table 107. Biken Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 108. Biken Varicella Vaccine Product
Table 109. Biken Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Varicella Vaccine Distributors List
Table 113. Varicella Vaccine Customers List
Table 114. Varicella Vaccine Market Trends
Table 115. Varicella Vaccine Market Drivers
Table 116. Varicella Vaccine Market Challenges
Table 117. Varicella Vaccine Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Product Picture of Varicella Vaccine
Figure 2. Global Varicella Vaccine Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Varicella Vaccine Market Share by Type: 2025 & 2032
Figure 4. Injection Product Picture
Figure 5. Freeze-Dried Powder Product Picture
Figure 6. Global Varicella Vaccine Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Varicella Vaccine Market Share by Application: 2025 & 2032
Figure 8. Kids Injection
Figure 9. Adults Injection
Figure 10. Global Varicella Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 11. Global Varicella Vaccine Market Size (US$ Million), 2021–2032
Figure 12. Global Varicella Vaccine Sales (M Doses), 2021–2032
Figure 13. Global Varicella Vaccine Average Price (USD/Dose), 2021–2032
Figure 14. Varicella Vaccine Report Years Considered
Figure 15. Varicella Vaccine Sales Share by Manufacturers in 2025
Figure 16. Global Varicella Vaccine Revenue Share by Manufacturers in 2025
Figure 17. Top 5 and Top 10 Global Varicella Vaccine Players: Market Share by Revenue in Varicella Vaccine in 2025
Figure 18. Varicella Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 19. Global Varicella Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 20. North America Varicella Vaccine Sales Market Share by Country (2021–2032)
Figure 21. North America Varicella Vaccine Revenue Market Share by Country (2021–2032)
Figure 22. U.S. Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 23. Canada Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Europe Varicella Vaccine Sales Market Share by Country (2021–2032)
Figure 25. Europe Varicella Vaccine Revenue Market Share by Country (2021–2032)
Figure 26. Germany Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. France Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. U.K. Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Italy Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Russia Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Asia Pacific Varicella Vaccine Sales Market Share by Region (2021–2032)
Figure 32. Asia Pacific Varicella Vaccine Revenue Market Share by Region (2021–2032)
Figure 33. China Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Japan Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. South Korea Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. India Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Australia Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. China Taiwan Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Indonesia Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Thailand Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Malaysia Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Latin America Varicella Vaccine Sales Market Share by Country (2021–2032)
Figure 43. Latin America Varicella Vaccine Revenue Market Share by Country (2021–2032)
Figure 44. Mexico Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Brazil Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Argentina Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Varicella Vaccine Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Varicella Vaccine Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Varicella Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Varicella Vaccine by Type (2021–2032)
Figure 53. Global Revenue Market Share of Varicella Vaccine by Type (2021–2032)
Figure 54. Global Varicella Vaccine Price (USD/Dose) by Type (2021–2032)
Figure 55. Global Sales Market Share of Varicella Vaccine by Application (2021–2032)
Figure 56. Global Revenue Market Share of Varicella Vaccine by Application (2021–2032)
Figure 57. Global Varicella Vaccine Price (USD/Dose) by Application (2021–2032)
Figure 58. Varicella Vaccine Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Varicella Vaccine market?
The top companies in the global Varicella Vaccine market are Merck、GSK、Shanghai Institute.
What was the global market size of Varicella Vaccine in 2032?
What was the global market size of Varicella Vaccine in 2026?
Which region is expected to have the highest market share?
What is the annual compound growth rate of the global Varicella Vaccine market size from 2026 to 2032?
Related Reports
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Varicella Vaccine market size was US$ 5185 million in 2025 and is forecast to reach a readjusted size of US$ 8708 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 79
USD 4250.00
(Single User License)
Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Varicella Vaccine was estimated to be worth US$ 5185 million in 2025 and is projected to reach US$ 8708 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 96
USD 3950.00
(Single User License)
Global Varicella Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Varicella Vaccine market is projected to grow from US$ 4845 million in 2024 to US$ 8137 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-09-11
Pages: 149
USD 4900.00
(Single User License)
Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Varicella Vaccine was estimated to be worth US$ 4845 million and is forecast to reach approximately US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 135
USD 5900.00
(Single User License)
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Varicella Vaccine market size was US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-03-19
Pages: 77
USD 4250.00
(Single User License)
Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Varicella Vaccine was estimated to be worth US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 95
USD 3950.00
(Single User License)
Global Varicella Vaccine Market Research Report 2025
The global market for Varicella Vaccine was valued at US$ 4845 million in the year 2024 and is projected to reach a revised size of US$ 8137 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published Date: 2025-01-16
Pages: 80
USD 2900.00
(Single User License)
Global Varicella Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-17
Pages: 140
USD 5600.00
(Single User License)
Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-16
Pages: 130
USD 5900.00
(Single User License)
Global Varicella Vaccine Market Insights, Forecast to 2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-07
Pages: 87
USD 4900.00
(Single User License)
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Varicella Vaccine market size was US$ 5185 million in 2025 and is forecast to reach a readjusted size of US$ 8708 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 79
USD 4250.00 (Single User License)Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Varicella Vaccine was estimated to be worth US$ 5185 million in 2025 and is projected to reach US$ 8708 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-04
Pages: 96
USD 3950.00 (Single User License)Global Varicella Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Varicella Vaccine market is projected to grow from US$ 4845 million in 2024 to US$ 8137 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-09-11
Pages: 149
USD 4900.00 (Single User License)Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Varicella Vaccine was estimated to be worth US$ 4845 million and is forecast to reach approximately US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 135
USD 5900.00 (Single User License)Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Varicella Vaccine market size was US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-03-19
Pages: 77
USD 4250.00 (Single User License)Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Varicella Vaccine was estimated to be worth US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 95
USD 3950.00 (Single User License)Global Varicella Vaccine Market Research Report 2025
The global market for Varicella Vaccine was valued at US$ 4845 million in the year 2024 and is projected to reach a revised size of US$ 8137 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published: 2025-01-16
Pages: 80
USD 2900.00 (Single User License)Global Varicella Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-17
Pages: 140
USD 5600.00 (Single User License)Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-16
Pages: 130
USD 5900.00 (Single User License)Global Varicella Vaccine Market Insights, Forecast to 2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-07
Pages: 87
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 2900.00
USD 4350.00
USD 5800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now